Global assessment of hepatic safety in novel immunotherapies: a systematic review and meta-analysis.

ABSTRACT:

Background

This study explored whether integrating innovative immunotherapies targeting costimulatory or co-inhibitory pathways beyond standard PD-1, PD-L1, and CTLA-4 treatments affects hepatic adverse events. We further analyzed liver-related side effects in patients with cancer receiving these novel therapies alone or in combination with others.

Methods

Clinical studies on immunotherapies targeting molecules such as LAG-3, TIGIT, TIM-3, VISTA, CD47, ICOS, CD40, and B7-H3 were retrieved from PubMed, Embase, Cochrane Library, and Web of Science. Data from eligible studies that reported liver-related adverse events until May 2024 were included.

Results

This analysis included 63 studies involving 7,327 patients. Among these, randomized controlled trials demonstrated th

SUBMITTER: Ye M 

PROVIDER: S-EPMC12873479 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature